Clinical Characters of ITP Patients with ICH
| . | Total . | Training Cohort . | Test Cohort . | P . |
|---|---|---|---|---|
| Patients, n | 142 | 107 | 35 | |
| 30-d mortality | 48 (33.803) | 39 (36.449) | 9 (25.714) | .244 |
| Demographic features | ||||
| Male, n (%) | 47 (33.099) | 35 (32.710) | 12 (34.286) | .863 |
| Age (yr), median (IQR) | 53 (35-64) | 53 (35-65) | 49 (29-59) | .475 |
| Comorbidity, n (%) | ||||
| Hypertension | 22 (15.603) | 15 (14.019) | 7 (20.588) | .358 |
| Diabetes mellitus | 16 (11.348) | 15 (14.019) | 1 (2.941) | .076 |
| Impaired renal function | 3 (2.128) | 3 (2.804) | 0 | — |
| Alcohol use (>80 g/d) | 2 (1.418) | 2 (1.869) | 0 | — |
| Previous stroke | 4 (2.817) | 3 (2.804) | 1 (2.857) | .987 |
| Previous infections | 16 (11.268) | 10 (9.346) | 6 (17.143) | .205 |
| Serious infections | 21 (14.789) | 15 (14.019) | 6 (17.143) | .651 |
| Clinical features related to ITP | ||||
| Platelet count at ITP diagnosis ×109/L, median (IQR) | 9 (4-20) | 9 (4-20) | 9 (5-20) | .848 |
| ITP duration | — | — | — | .684 |
| Within 3 mo, n (%) | 33 (23.239) | 23 (21.495) | 10 (28.571) | — |
| 3-12 mo, n (%) | 14 (9.859) | 11 (10.280) | 3 (8.571) | — |
| >12 mo, n (%) | 95 (66.901) | 73 (68.224) | 22 (62.857) | — |
| Previous treatment, n (%) | ||||
| No treatment received | 30 (21.127) | 25 (23.364) | 5 (14.286) | .253 |
| Glucocorticoid resistance, n (%) | 44 (31.206) | 33 (31.132) | 11 (31.429) | .974 |
| Events before ICH, n (%) | ||||
| Head trauma or surgery | 12 (8.451) | 10 (9.346) | 2 (5.714) | .503 |
| Medications interfering with hemostasis | 12 (8.451) | 11 (10.280) | 1 (2.857) | .171 |
| Anticoagulant and antiplatelet drugs | 8 (5.634) | 8 (7.477) | 0 | — |
| NSAIDs | 6 (4.225) | 5 (4.673) | 1 (2.857) | .643 |
| Preceding bleeding events* | 120 (84.507) | 89 (83.178) | 31 (88.571) | .444 |
| Time interval to ICH, mo | 1 (0,2) | 1 (0,3) | 1 (0,2) | .211 |
| Severity of bleeding | — | — | — | .917 |
| Mild (skin manifestations or no bleeding) | 54 (38.028) | 40 (37.383) | 14 (40.000) | — |
| Moderate (visible mucosal bleeding) | 31 (21.831) | 23 (21.495) | 8 (22.857) | — |
| Severe (organ or internal mucosal bleeding) | 57 (40.141) | 44 (41.121) | 13 (37.143) | — |
| Life-threatening bleeding events | 22 (15.493) | 15 (14.019) | 7 (20.000) | .396 |
| Clinical features for ICH | ||||
| Platelet count at ICH ×109/L, median (IQR) | 7 (2-20) | 7 (3-15) | 6 (1-23) | .558 |
| Type of ICH, n (%)* | ||||
| IPH | 75 (58.140) | 57 (59.375) | 18 (54.545) | .628 |
| SAH | 30 (23.256) | 24 (25.000) | 6 (18.182) | .424 |
| SDH | 28 (21.705) | 21 (21.875) | 7 (21.212) | .936 |
| EDH | 3 (2.326) | 3 (3.125) | 0 | — |
| GCS on admission, n (%) | — | — | — | .918 |
| 15 | 79 (55.634) | 59 (55.140) | 20 (57.143) | — |
| 13-14 | 27 (19.014) | 21 (19.626) | 6 (17.143) | — |
| 9-12 | 25 (17.606) | 18 (16.822) | 7 (20.000) | — |
| ≤8 | 11 (7.746) | 9 (8.411) | 2 (5.714) | — |
| . | Total . | Training Cohort . | Test Cohort . | P . |
|---|---|---|---|---|
| Patients, n | 142 | 107 | 35 | |
| 30-d mortality | 48 (33.803) | 39 (36.449) | 9 (25.714) | .244 |
| Demographic features | ||||
| Male, n (%) | 47 (33.099) | 35 (32.710) | 12 (34.286) | .863 |
| Age (yr), median (IQR) | 53 (35-64) | 53 (35-65) | 49 (29-59) | .475 |
| Comorbidity, n (%) | ||||
| Hypertension | 22 (15.603) | 15 (14.019) | 7 (20.588) | .358 |
| Diabetes mellitus | 16 (11.348) | 15 (14.019) | 1 (2.941) | .076 |
| Impaired renal function | 3 (2.128) | 3 (2.804) | 0 | — |
| Alcohol use (>80 g/d) | 2 (1.418) | 2 (1.869) | 0 | — |
| Previous stroke | 4 (2.817) | 3 (2.804) | 1 (2.857) | .987 |
| Previous infections | 16 (11.268) | 10 (9.346) | 6 (17.143) | .205 |
| Serious infections | 21 (14.789) | 15 (14.019) | 6 (17.143) | .651 |
| Clinical features related to ITP | ||||
| Platelet count at ITP diagnosis ×109/L, median (IQR) | 9 (4-20) | 9 (4-20) | 9 (5-20) | .848 |
| ITP duration | — | — | — | .684 |
| Within 3 mo, n (%) | 33 (23.239) | 23 (21.495) | 10 (28.571) | — |
| 3-12 mo, n (%) | 14 (9.859) | 11 (10.280) | 3 (8.571) | — |
| >12 mo, n (%) | 95 (66.901) | 73 (68.224) | 22 (62.857) | — |
| Previous treatment, n (%) | ||||
| No treatment received | 30 (21.127) | 25 (23.364) | 5 (14.286) | .253 |
| Glucocorticoid resistance, n (%) | 44 (31.206) | 33 (31.132) | 11 (31.429) | .974 |
| Events before ICH, n (%) | ||||
| Head trauma or surgery | 12 (8.451) | 10 (9.346) | 2 (5.714) | .503 |
| Medications interfering with hemostasis | 12 (8.451) | 11 (10.280) | 1 (2.857) | .171 |
| Anticoagulant and antiplatelet drugs | 8 (5.634) | 8 (7.477) | 0 | — |
| NSAIDs | 6 (4.225) | 5 (4.673) | 1 (2.857) | .643 |
| Preceding bleeding events* | 120 (84.507) | 89 (83.178) | 31 (88.571) | .444 |
| Time interval to ICH, mo | 1 (0,2) | 1 (0,3) | 1 (0,2) | .211 |
| Severity of bleeding | — | — | — | .917 |
| Mild (skin manifestations or no bleeding) | 54 (38.028) | 40 (37.383) | 14 (40.000) | — |
| Moderate (visible mucosal bleeding) | 31 (21.831) | 23 (21.495) | 8 (22.857) | — |
| Severe (organ or internal mucosal bleeding) | 57 (40.141) | 44 (41.121) | 13 (37.143) | — |
| Life-threatening bleeding events | 22 (15.493) | 15 (14.019) | 7 (20.000) | .396 |
| Clinical features for ICH | ||||
| Platelet count at ICH ×109/L, median (IQR) | 7 (2-20) | 7 (3-15) | 6 (1-23) | .558 |
| Type of ICH, n (%)* | ||||
| IPH | 75 (58.140) | 57 (59.375) | 18 (54.545) | .628 |
| SAH | 30 (23.256) | 24 (25.000) | 6 (18.182) | .424 |
| SDH | 28 (21.705) | 21 (21.875) | 7 (21.212) | .936 |
| EDH | 3 (2.326) | 3 (3.125) | 0 | — |
| GCS on admission, n (%) | — | — | — | .918 |
| 15 | 79 (55.634) | 59 (55.140) | 20 (57.143) | — |
| 13-14 | 27 (19.014) | 21 (19.626) | 6 (17.143) | — |
| 9-12 | 25 (17.606) | 18 (16.822) | 7 (20.000) | — |
| ≤8 | 11 (7.746) | 9 (8.411) | 2 (5.714) | — |
EDH, epidural hemorrhage; GCS, Glasgow Coma Scale; IQR, interquartile range; NSAIDs, nonsteroidal antiinflammatory drugs; SDH, subdural hemorrhage.
Thirteen patients missed detailed records of ICH location: 9 patients were in the training cohort, and 4 patients were in the test cohort.